Public Release: 

Timing possible treatments against Alzheimer's disease

PLOS

Alzheimer Disease (AD) is characterized by hallmark lesions called amyloid plaques in the brain. The plaques are formed by the aggregation of small peptides (proteins), called amyloid beta peptide (Abeta), that are produced when a larger protein called amyloid precursor protein (APP) is cleaved by the action of two enzymes, beta-APP cleaving enzyme and gamma-secretase. Many scientists are developing inhibitors of these enzymes as possible therapies. In the meantime, other researchers are trying to test whether and how such approaches might work, at least in principle. Joanna Jankowsky, David Borchelt, and colleagues from institutes across the country, including Johns Hopkins School of Medicine, the Mayo Clinic Jacksonville, the National Cancer Institute, University of Florida, and the California Institute of Technology have some answers.

As they report in the international open-access medical journal PLoS Medicine, they have engineered mice to continuously produce Abeta in their brains. The production can be switched off by giving the mice the antibiotic tetracycline in their drinking water. This switch-off at a certain point is similar to what would happen to human patients who would receive enzyme inhibitors once diagnosed with AD. Without tetracycline, the brains of the mice at six months of age are loaded with amyloid plaques. When the researchers switched the system off after some initial plaques had formed, they found two things: the existing plaques didn't grow or spread to other areas of the brain, but they did not go away either.

As always, results from animal models cannot simply be extrapolated to human disease. However, this study suggests that treatment with drugs that lower production of Abeta can prevent progression of AD but not reverse the disease. While overall encouraging, the results emphasize the importance of early treatment with drugs that inhibit Abeta production.

###

Citation: Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, et al. (2005) Persistent amyloidosis following suppression of Ab production in a transgenic model of Alzheimer disease. PLoS Med 2(12): e355.

CONTACTS:

Joanna Jankowsky
California Institute of Technology
Mail Code 156-29
1200 E. California Blvd.
Pasadena, CA USA 91125
+1-626-395-6884
+1-626-564-8709 (fax)
jlj2@caltech.edu

David Borchelt
Johns Hopkins University School of Medicine
558 Ross Research Building
1721 E. Madison Ave.
Baltimore, MD USA 21205
borchelt@mbi.ufl.edu

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.